FCM
DRTX

Farallon Capital Management’s DURATA THERAPEUTICS INC COM STK (DE) DRTX Stock Holding History

Farallon Capital Management’s Portfolio DRTX Stock Details DRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-30,000
Closed -$216K – 89
2013
Q2 		$216K Buy
+30,000
New +$220K ﹤0.01% 82

Other funds holding DRTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Farallon Capital Management's DRTX Position: Q3 2013 in Review

Farallon Capital Management sold out of DURATA THERAPEUTICS INC COM STK (DE) (DRTX) in Q3 2013, closing a stake of 30,000 shares — an estimated $216K sold.

Farallon Capital Management first reported a position in DRTX in Q2 2013 and held it in 1 quarter. The position peaked at $216K in Q2 2013. 48 funds tracked by Wall St. Rank hold DRTX as of Q3 2013.

  • Farallon Capital Management reported no remaining DURATA THERAPEUTICS INC COM STK (DE) position as of Q3 2013 after selling out during the quarter.
  • Farallon Capital Management sold 30,000 DURATA THERAPEUTICS INC COM STK (DE) shares in Q3 2013, an estimated $216K.
  • Farallon Capital Management first reported a position in DURATA THERAPEUTICS INC COM STK (DE) in Q2 2013 and held it in 1 quarter.
  • Farallon Capital Management's DURATA THERAPEUTICS INC COM STK (DE) position peaked at $216K in Q2 2013.
  • 48 funds tracked by Wall St. Rank held DURATA THERAPEUTICS INC COM STK (DE) as of Q3 2013.

Based on Farallon Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.